Tag: PTC Therapeutics
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering $1.5 billion from the Evrysdi royalty stream. ... Read More
PTC Therapeutics wins Russian approval for Translarna for nmDMD
US-based PTC Therapeutics has secured marketing approval in Russia for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The approval for ... Read More
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics
US biopharma company PTC Therapeutics has completed its $200 million acquisition of Agilis Biotherapeutics, a biotechnology company engaged in the development of gene therapies for ... Read More